Mumbai : Veerhealth Care Limited (BSE: VEERHEALTH), Ayuveer, backed by Veerhealth Care's expertise in Ayurveda, specializes in crafting ayurvedic medicines and oral care products with natural ingredients. With a focus on quality and affordability, Ayuveer aims to offer an exceptional and safe daily care experience to its customers.
Q2 FY25 Standalone Financial Highlights
- Total Income of ₹ 5.39 Cr, YoY growth of 27.14%
- EBITDA of ₹ 0.73 Cr, YoY growth of 16.06%
- EBITDA Margin of 13.55%
- Net Profit of ₹ 0.30 Cr
- Net Profit Margin of 5.54%
Key Highlights For H1 FY25
- Expands U.S.A. Operations with New Export Order worth around ₹ 0.34 Cr from a leading institutional supplier in the United States of America.
- Manufactured and shipped orders worth approximately ₹ 3.00 Cr
- Secured Export Order Worth around ₹ 0.84 Cr in Oral Care Category from Top USA Institutional Supplier
- Expansion and purchase of Additional 27,451 sq. ft. of Land adjacent to its current manufacturing facility to Meet Growing Demand and Enhance Production Capabilities. The new facility will be equipped with plastic blow molding and injection molding machines, allowing for backward integration by producing packaging & complementing materials internally.
- Secured Order Worth ₹ 1.21 Cr in Hair Care Category from Leading Corporate Healthcare Client.
- Secures Significant Export Order from Top US Institutional Supplier of worth ₹ 0.89 Cr
- Ayuveer’s products have successfully completed the onboarding process on Nykaa’s mobile application and website.
- Secures Significant Export Order from Top US Institutional Supplier of worth ₹ 1.65 Cr
- Secures New order worth ₹ 57.36 Lakhs from a Chain of Retail Indian Healthcare company.
Commenting on the financial performance, Mr. Bhavin Shah - Managing Director of Veerhealth Care Limited, said, “I am delighted with the strides we have made in H1 FY25, driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. The growth in our Export Sales and the addition of new product categories have significantly bolstered our position in the global and local markets.
Our ability to secure multiple high-value export orders, including those from top institutional suppliers, underscores the trust in our product quality and commitment to excellence. The expansion of our manufacturing footprint further reflects our proactive approach to meeting growing demand and enhancing our production capabilities. These achievements are a testament to our strategy and pave the way for sustained growth and value creation in the coming quarters."
The Company has renovated its existing plant in Vapi, Gujarat to set up a bigger plant which will be compliant with CGMP norms as required by the US FDA.